Leerink Partnrs Brokers Lower Earnings Estimates for Xencor

Xencor, Inc. (NASDAQ:XNCR) – Equities research analysts at Leerink Partnrs cut their Q2 2025 EPS estimates for Xencor in a note issued to investors on Wednesday, May 7th. Leerink Partnrs analyst J. Chang now anticipates that the biopharmaceutical company will post earnings per share of ($0.77) for the quarter, down from their previous estimate of ($0.66). The consensus estimate for Xencor’s current full-year earnings is ($3.68) per share. Leerink Partnrs also issued estimates for Xencor’s Q3 2025 earnings at ($0.76) EPS, Q4 2025 earnings at ($0.69) EPS, FY2025 earnings at ($2.88) EPS and FY2026 earnings at ($3.24) EPS.

A number of other research analysts have also commented on the company. StockNews.com lowered Xencor from a “hold” rating to a “sell” rating in a research report on Friday, March 14th. Wells Fargo & Company lowered their price target on Xencor from $37.00 to $33.00 and set an “overweight” rating on the stock in a research report on Friday, February 28th. William Blair began coverage on shares of Xencor in a report on Monday, April 21st. They issued an “outperform” rating on the stock. Barclays lowered their price target on shares of Xencor from $22.00 to $6.00 and set an “underweight” rating on the stock in a report on Thursday, May 8th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $31.00 price objective on shares of Xencor in a report on Wednesday, April 30th. Two equities research analysts have rated the stock with a sell rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $29.50.

Xencor Trading Down 7.5%

Shares of Xencor stock opened at $8.11 on Monday. The company has a 50-day simple moving average of $10.63 and a 200 day simple moving average of $17.52. Xencor has a 12-month low of $7.16 and a 12-month high of $27.24. The stock has a market capitalization of $577.04 million, a P/E ratio of -2.53 and a beta of 0.99. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 0.01.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.06). Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The firm had revenue of $32.73 million during the quarter, compared to analyst estimates of $23.44 million. During the same period last year, the company earned ($1.11) EPS. The company’s revenue was up 104.6% on a year-over-year basis.

Institutional Investors Weigh In On Xencor

Institutional investors have recently modified their holdings of the company. Sterling Capital Management LLC lifted its position in shares of Xencor by 732.4% during the 4th quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 1,040 shares during the period. GF Fund Management CO. LTD. bought a new position in Xencor in the fourth quarter worth approximately $34,000. GAMMA Investing LLC raised its position in shares of Xencor by 31.0% during the fourth quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 508 shares during the period. CWM LLC increased its stake in Xencor by 195.5% during the 1st quarter. CWM LLC now owns 3,372 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 2,231 shares in the last quarter. Finally, KBC Group NV raised its holdings in Xencor by 26.0% during the fourth quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company’s stock worth $90,000 after buying an additional 813 shares during the last quarter.

Insider Activity at Xencor

In other Xencor news, EVP Nancy Valente sold 4,616 shares of the company’s stock in a transaction that occurred on Friday, May 2nd. The shares were sold at an average price of $11.03, for a total value of $50,914.48. Following the completion of the transaction, the executive vice president now directly owns 49,169 shares in the company, valued at approximately $542,334.07. This represents a 8.58% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 4.76% of the stock is currently owned by insiders.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.